Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 137.50
Bid: 135.00
Ask: 140.00
Change: -2.50 (-1.79%)
Spread: 5.00 (3.704%)
Open: 140.00
High: 137.50
Low: 133.00
Prev. Close: 140.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of 2021 Full-Year Results and Annual Report

7 Mar 2022 07:00

RNS Number : 7637D
Faron Pharmaceuticals Oy
07 March 2022
 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

 

Notice of 2021 Full-Year Results and Annual Report

 

Press Release, March 7, 2022 at 09:00 AM (EET) / 07:00 AM (GMT) / 02:00 AM (EST)

 

TURKU, FINLAND / BOSTON, MA Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, will publish its audited full-year results for the twelve months ended December 31, 2021 on Friday, March 25, 2022 at 9:00 am EET, 7:00 am GMT, 3:00 am EDT. The Annual Report 2021, including audited financial statements for the full year, will be published on the same day.

 

A virtual briefing and Q&A session for analysts will be hosted by Dr. Markku Jalkanen, Chief Executive Officer of Faron, and Toni Hänninen, Chief Financial Officer of Faron, at 2:00 pm EET / 12:00 pm GMT / 8:00 am EDT on the day of results. The Full-year results release for 2021, presentation, webcast details, and Annual Report 2021 will be made available at www.faron.com/investors. A replay of the analyst briefing will be made available shortly afterwards.

 

For more information please contact:

 

Media / Investor Contact

Faron Pharmaceuticals

Eric Van Zanten

Head of Communications

eric.vanzanten@faron.com

investor.relations@faron.com

Phone: +1 (610) 529-6219

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

faron@consilium-comms.com

Phone: +44 (0)20 3709 5700

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.

 

Forward Looking Statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should", "expect", "hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In particular, the early data from initial patients in the MATINS trial may not be replicated in larger patient numbers and the outcome of clinical trials may not be favourable or clinical trials over and above those currently planned may be required before the Company is able to apply for marketing approval for a product. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABRGDXIDGDGDS
Date   Source Headline
12th Sep 20187:00 amRNSNew data published on Clever-1 function
8th Aug 201811:05 amRNSSecond Price Monitoring Extn
8th Aug 201811:00 amRNSPrice Monitoring Extension
8th Aug 20187:00 amRNSNotice of Interim Results
9th Jul 20188:45 amRNSHolding(s) in Company
28th Jun 20187:00 amRNSClevegen successful toxicity studies
22nd Jun 20187:00 amRNSHoldings in Company
21st Jun 20183:58 pmRNSDirector/PDMR Shareholding
21st Jun 20189:00 amRNSPrice Monitoring Extension
21st Jun 20187:40 amRNSDirector/PDMR Shareholding
20th Jun 20182:05 pmRNSSecond Price Monitoring Extn
20th Jun 20182:00 pmRNSPrice Monitoring Extension
20th Jun 20188:43 amRNSHolding(s) in Company
18th Jun 20183:42 pmRNSHoldings in Company
15th Jun 20184:40 pmRNSSecond Price Monitoring Extn
15th Jun 20184:35 pmRNSPrice Monitoring Extension
14th Jun 201811:05 amRNSSecond Price Monitoring Extn
14th Jun 201811:00 amRNSPrice Monitoring Extension
14th Jun 20187:00 amRNSBiomarker analysis of Phase III INTEREST trial
31st May 20182:33 pmRNSResult of AGM
31st May 20187:00 amRNSAGM Statement
16th May 20185:53 pmRNSPDMR Shareholding
15th May 20183:14 pmRNSDirector/PDMR Shareholding
15th May 20182:05 pmRNSSecond Price Monitoring Extn
15th May 20182:00 pmRNSPrice Monitoring Extension
15th May 20181:16 pmRNSHoldings in Company
11th May 20184:51 pmRNSHolding(s) in Company
11th May 20181:37 pmRNSHolding(s) in Company
11th May 20181:34 pmRNSHolding(s) in Company
11th May 20187:00 amRNSUpdate on the Phase III INTEREST trial
10th May 201810:05 amRNSNotice of AGM
9th May 20184:40 pmRNSSecond Price Monitoring Extn
9th May 20184:35 pmRNSPrice Monitoring Extension
9th May 201812:54 pmRNSHoldings in Company
8th May 20189:05 amRNSSecond Price Monitoring Extn
8th May 20189:00 amRNSPrice Monitoring Extension
8th May 20187:00 amRNSTop line data from the Phase III INTEREST trial
8th May 20187:00 amRNSFinal Results for the year ended 31 December 2017
25th Apr 201812:43 pmRNSHoldings in Company
21st Mar 20187:00 amRNSNotice of Full Year Results
6th Mar 201812:54 pmRNSHolding(s) in Company
5th Mar 201810:12 amRNSHolding(s) in Company
2nd Mar 20181:30 pmRNSHolding(s) in Company
2nd Mar 20181:25 pmRNSHolding(s) in Company
1st Mar 201812:42 pmRNSHoldings in Company
1st Mar 201812:41 pmRNSHoldings in Company
26th Feb 20181:37 pmRNSIssue of Equity
21st Feb 20183:31 pmRNSResults of Placing & Issue of Equity
21st Feb 20187:00 amRNSFaron hosts R&D Day today in London
16th Feb 20187:00 amRNSProposed Placing to raise up to £15m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.